DOI: 10.12890/2022_003636

Transient Leukopenia Induced by Combination Therapy for Severe SARS-CoV-2 Pneumonia

Authors

  • Sierra Sullivan Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
  • Natnicha Leelaviwat Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
  • Jesus Davalos Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
  • Abbie Evans Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
  • Mahmoud Abdelnabi Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
  • Neha Mittal Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA

Sierra.Lynn.Sullivan@ttuhsc.edu

Keywords

SAR-CoV-2 pneumonia, transient leukopenia, remdesivir, baricitinib, dexamethasone

Abstract

Treatment strategies for patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to be heavily researched and ever-changing. Recent data has suggested that combination therapy with dexamethasone, remdesivir and baricitinib could decrease the severity and length of illness in patients with severe SARS-CoV-2. However; the data regarding the safety and side effects related to this combination therapy are limited to case reports. The purpose of this case report is to highlight a potentially life-threatening side effect of one or all medications mentioned above.

View the entire article

Downloads

References

  1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19. N Engl J Med 2020;383:1813–1826.
  2. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021;384:795–807.
  3. Tsuchiya K, Fujisawa T, Mochizuka Y, Takuma S, Oishi K, Endo Y, et al. Transient leukocytopenia following combination therapy for COVID-19. Respir Investig 2022;60:158–161.
  4. Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee S-S. The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies. Front Pharmacol 2021;12:704205.
  5. McCullough PA, Alexander PE, Armstrong R, Arvinte C, Bain AF, Bartlett RP, et al. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Rev Cardiovasc Med 2020;21:517.
  6. National Institutes of Health. COVID-19 Treatment Guidelines 2022. Available from: https://www.covid19treatmentguidelines.nih.gov/ (accessed 3 October 2022).
  7. Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Semin Hematol 2013;50:198–206.

Published

2022-10-25

Issue

Vol. 9 No. 10 (2022)

Categories

How to Cite

1.
Sullivan S, Leelaviwat N, Davalos J, Evans A, Abdelnabi M, Mittal N. Transient Leukopenia Induced by Combination Therapy for Severe SARS-CoV-2 Pneumonia. EJCRIM [Internet]. 2022 Oct. 25 [cited 2026 Nov. 3];9(10). Available from: https://ejcrim.com/index.php/ejcrim/article/view/3636

Most read articles by the same author(s)